次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

アトピー性皮膚炎治療薬の世界市場:薬剤分類別、主要7ヶ国別2022年予測

Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics), By RoA, And Segment Forecasts, 2016 - 2022

出版元:Grand View Research(米国)LinkIcon出版元について
発行年:2018年8月
定価 Single User License(1名様ライセンス)US$4,450(米国ドル)/Multi User License(5名様)$6,450 /Enterprise License $8,450
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email (※PDFコンテンツ保護/DRM設定あり)
当調査レポートは英文 84ページになります。
商品コード:GRAN042

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
アトピー性皮膚炎治療薬の世界市場規模は今後2022年に64億1000万ドルに達するとレポートでは予測しています。
当レポートでは、2022年に至るアトピー性皮膚炎治療薬市場の世界市場予測(市場規模US$)、薬剤分類別市場(コルチコステロイド、カルシニューリン阻害薬、PDE4阻害薬、生物学的製剤、その他)、投与経路別市場(局所、注射、経口)、主要7か国別市場など、詳細な市場予測データと分析を掲載しています。また市場分析、競合状況、主要メーカー企業5社プロフィール動向などの情報も交えて、市場の現在と今後展開を予測分析していきます。

【レポート構成概要】pic_GRAN_cover-new-3.png
◆ アトピー性皮膚炎治療薬の世界市場予測2016-2022年
・市場規模(US$)

◆ 薬剤分類別、市場-2022年
・コルチコステロイド
・カルシニューリン阻害薬
・PDE4阻害薬
・生物学的製剤
・その他
※(市場規模US$)

◆ 投与経路別、市場-2022年
・局所
・注射
・経口
※(市場規模US$)

◆ 主要7ヶ国、国別市場-2022年
・米国、英国、ドイツ、スペイン
・イタリア、フランス、日本
・その他地域(rest of the world)
※ 国別に治療薬別、投与経路別の細分化データ掲載、詳細は目次参照
※ (市場規模US$)

◆ 市場分析
・市場ドライバー/障壁
・業界構造分析(ファイブフォース分析)
・PESTEL分析
・競合状況

◆ 研究開発動向
パイプライン状況
・開発中の薬
・主要研究開発動向
-PDE4阻害剤
-JAK阻害剤
-生物学的製剤
有望薬
・後期開発パイプライン
・革新的新薬概要
-Tralokinumab
-PF-04965842
-Dupixent

◆ アトピー性皮膚炎治療薬の主要企業プロフィール動向
・BAYER
・LEO PHARMA
・MYLA
・PFIZER
・SANOFI

(全84貢)
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics), By RoA, And Segment Forecasts, 2016 - 2022

Table of Contents

Chapter 1 Research Methodology

1.1 Information Procurement
1.2 Information or Data Analysis
1.2.1 Market Formulation & Validation

Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology

3.1 Disease Primer
3.1.1 Symptoms
3.1.2 Risk Factors
3.1.3 Complications
3.2 Epidemiology by Indications
3.3 Current Prevalence for Seven Major Markets (U.S., Japan, EU5)
3.4 Current Incidence for Seven Major Markets (U.S., Japan, EU5)
3.5 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)

Chapter 4 Global Atopic Dermatitis Drugs Market Overview

4.1 Introduction and Market Overview
4.1.1 Segmentation, by Mode of Administration
4.1.1.1 Topical
4.1.1.2 Injectable
4.1.1.3 Oral
4.1.2 Segmentation, by Drug Class
4.1.2.1 Corticosteroids
4.1.2.2 Calcineurin Inhibitors
4.1.2.3 PDE4 Inhibitors
4.1.2.4 Biologics
4.1.2.5 Others
4.1.3 Market Size and Forecast
4.1.4 Sales Performance
4.1.5 Market Share Distribution
4.1.6 Market Dynamics among Leading Brands
4.2 Patent Expiry Schedule
4.3 Drivers and Challenges
4.4 M&A, Deal Landscape (YTD 2013-2018)
4.5 Pricing and Reimbursement
4.6 SWOT Analysis

Chapter 5 Atopic Dermatitis Drugs Market: Pipeline Intelligence

5.1 Pipeline Landscape
5.1.1 Drugs in Development
5.1.2 Key R&D Trends
5.1.2.1 PDE4 inhibitor
5.1.2.2 JAK inhibitor
5.1.2.3 Biologics
5.2 Promising Drugs
5.2.1 Late-Stage Pipeline
5.2.2 Profile of Disruptive Drugs
5.2.2.1 Tralokinumab
5.2.2.2 PF-04965842
5.2.2.3 Dupixent

Chapter 6 Company Profiles

6.1 Bayer
6.1.1 Company Overview
6.1.2 Current Product Portfolio
6.1.3 Company - Key News Flow
6.1.4 Catalysts and Event Calendar
6.1.5 SWOT Analysis
6.2 LEO Pharma
6.2.1 Company Overview
6.2.2 Current Product Portfolio
6.2.3 Product Forecast Sales up to 2022
6.2.4 Company - Key News Flow
6.2.5 Pipeline View
6.2.6 Pipeline Forecast
6.2.7 Catalysts and Event Calendar
6.2.8 SWOT Analysis
6.3 Mylan
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales up to 2022
6.3.4 Company - Key News Flow
6.3.5 Catalysts and Event Calendar
6.3.6 SWOT Analysis
6.4 Pfizer
6.4.1 Company Overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales up to 2022
6.4.4 Company - Key News Flow
6.4.5 Pipeline View
6.4.6 Pipeline Forecast
6.4.7 Catalysts and Event Calendar
6.4.8 SWOT Analysis
6.5 Sanofi
6.5.1 Company Overview
6.5.2 Current Product Portfolio
6.5.3 Product Forecast Sales up to 2022
6.5.4 Company - Key News Flow
6.5.5 Pipeline View
6.5.6 Pipeline Forecast
6.5.7 Catalysts and Event Calendar
6.5.8 SWOT Analysis

Chapter 7 Market Outlook

7.1 What the Future Holds
7.2 Winners and Losers
7.3 Emerging Companies
7.4 The Road Ahead"

List of Tables

TABLE 1 Current Atopic Dermatitis Prevalence Across Seven Major Markets - 2016
TABLE 2 Current Atopic Dermatitis Incidence Across Seven Major Markets - 2016
TABLE 3 Forecast Atopic Dermatitis Prevalence Across Seven Major Markets, 2016 - 2022
TABLE 4 Forecast Atopic Dermatitis Incidence Across Seven Major Markets, 2016 - 2022
TABLE 5 Atopic Dermatitis Drugs Market Size and Forecast (in USD million)
TABLE 6 Geographic Sales Performance, by Seven Major Markets (in $million)
TABLE 7 Atopic Dermatitis Drugs Market, by Drug Class (in $million)
TABLE 8 Atopic Dermatitis Drugs Market, by Route of Administration (in $million)
TABLE 9 Forecast Sales of Leading Brands (in $million)
TABLE 10 Global Atopic Dermatitis Cancer Drugs Pipeline Forecast
TABLE 11 Atopic Dermatitis Drugs Sales Forecast, by Company (in $million)
TABLE 12 Atopic Dermatitis Drugs Market Share, by Company (in $million)
TABLE 13 Atopic Dermatitis Drugs Market: Patent Expiry Schedule
TABLE 14 Atopic Dermatitis Deal Landscape YTD (2013 - 2018)
TABLE 15 Atopic Dermatitis Drugs in Development
TABLE 16 Late-Stage Atopic Dermatitis Pipeline
TABLE 17 Profile of Disruptive Drug: Tralokinumab
TABLE 18 Profile of Disruptive Drug: PF-04965842
TABLE 19 Profile of Disruptive Drug: Dupixent
TABLE 20 Product Portfolio: Desonate
TABLE 21 Bayer Catalysts and Event Calendar
TABLE 22 Product Portfolio: Protopic
TABLE 23 Protopic Sales Forecast Through 2022
TABLE 24 LEO Pharma Pipeline View
TABLE 25 LEO Pharma Catalysts and Event Calendar
TABLE 26 Product Portfolio: Elidel
TABLE 27 Elidel Sales Forecast Through 2022
TABLE 28 Mylan Catalysts and Event Calendar
TABLE 29 Product Portfolio: Eucrisa
TABLE 30 Eucrisa Sales Forecast through 2022
TABLE 31 Pfizer Pipeline View
TABLE 32 Bayer Catalysts and Event Calendar
TABLE 33 Product Portfolio: Dupixent
TABLE 34 Dupixent Sales Forecast Through 2022
TABLE 35 Sanofi Pipeline View
TABLE 36 Bayer Catalysts and Event Calendar"

List of Figures

FIG. 1 Market Research Process
FIG. 2 Information Procurement
FIG. 3 Primary Research Pattern
FIG. 4 Market Research Approaches
FIG. 5 Value Chain Based Sizing & Forecasting
FIG. 6 QFD Modelling for Market Share Assessment
FIG. 7 Atopic Dermatitis Prevalence Across Seven Major Markets - 2016
FIG. 8 Atopic Dermatitis Incidence Across Seven Major Markets - 2016
FIG. 9 Market Segmentation & Scope
FIG. 10 Geographic Sales Performance, by Seven Major Markets 2016
FIG. 11 Atopic Dermatitis Drugs Market, Sales by Drug Class (in $million)
FIG. 12 Atopic Dermatitis Trend, by Drug Class
FIG. 13 Atopic Dermatitis Drugs Market, Sales by Route of Administration (in $million)
FIG. 14 U.S. Atopic Dermatitis Drugs Market Shares, by Drug Class (2016A - 2022E)
FIG. 15 U.K. Atopic Dermatitis Drugs Market Shares, by Drug Class (2016A - 2022E)
FIG. 16 Germany Atopic Dermatitis Drugs Market Shares, by Drug Class (2016A - 2022E)
FIG. 17 Spain Atopic Dermatitis Drugs Market Shares, by Drug Class (2016A - 2022E)
FIG. 18 Italy Atopic Dermatitis Drugs Market Shares, by Drug Class (2016A - 2022E)
FIG. 19 France Atopic Dermatitis Drugs Market Shares, by Drug Class (2016A - 2022E)
FIG. 20 Japan Atopic Dermatitis Drugs Market Shares, by Drug Class (2016A - 2022E)
FIG. 21 U.S. Atopic Dermatitis Drugs Market, Sales by Route of Administration (in $million)
FIG. 22 U.K. Atopic Dermatitis Drugs Market, Sales by Route of Administration (in $million)
FIG. 23 Germany Atopic Dermatitis Drugs Market, Sales by Route of Administration (in $million)
FIG. 24 Spain Atopic Dermatitis Drugs Market, Sales by Route of Administration (in $million)
FIG. 25 Italy Atopic Dermatitis Drugs Market, Sales by Route of Administration (in $million)
FIG. 26 France Atopic Dermatitis Drugs Market, Sales by Route of Administration (in $million)
FIG. 27 Japan Atopic Dermatitis Drugs Market, Sales by Route of Administration (in $million)
FIG. 28 Atopic Dermatitis Drugs Market Share, by Company (2016A - 2022E)
FIG. 29 Market Trends & Outlook
FIG. 30 Market Driver Relevance Analysis (Current & Future Impact)
FIG. 31 Market Restraint Relevance Analysis (Current & Future Impact)
FIG. 32 SWOT Analysis (Atopic Dermatitis Drugs Market)
FIG. 33 Pipeline Assets by Phase
FIG. 34 SWOT Analysis (Bayer)
FIG. 35 SWOT Analysis (LEO Pharma)
FIG. 36 SWOT Analysis (Mylan)
FIG. 37 SWOT Analysis (Pfizer)
FIG. 38 SWOT Analysis (Sanofi)

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。